Psychedeic-Chronicle-Logo

Suggestions

  • Psychedelic News
  • DMT
  • Ketamine
  • Mescaline
  • Psilocybin
  • CEO INTERVIEWS

Psychedeic-Chronicle-Logo

CYB003

Cybin-Announces-Dosing-of-First-Patients-in-Phase-1-2a-Clinical-Trial-of-CYB003-Psilocybin-Analog-for-Depression Psychedeic-Chronicle-Logo-White
Psychedelic News

Cybin Announces Dosing of First Patients in Phase 1/2a Clinical Trial of CYB003 Psilocybin Analog for Depression

Psychedelic biopharmaceutical company Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) announced today the dosing of the first two patients in the company’s Phase

August 30, 2022

Recent Posts

  • Choose Ketamine Complete Capital Raise to Expand Technology Platform
  • Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax
  • Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment
  • Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use
  • atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial

Recent Comments

No comments to show.

Popular

Choose Ketamine Complete Seed Capital Raise to Expand Technology Platform

Choose Ketamine Complete Capital Raise to Expand Technology Platform

In a major milestone for mental health care, Austin-based Choose

Biomind Labs Secure Pre-IND Meeting, Seek FDA Feedback on New Triptax Depression Treatment

Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax

The well-known psychedelic biotech company Biomind Labs Inc. (NEO: BMND)

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced

Psychedeic-Chronicle-Logo

© 2022 PSYCHEDELIC CHRONICLE
ALL RIGHTS RESERVED.

  • Psychedelic News
  • DMT
  • Ketamine
  • Mescaline
  • Psilocybin
  • CEO INTERVIEWS